By Dr Briony Kate Larance

Journal articles

Campbell G; Lintzeris N; Gisev N; Larance B; Pearson S; Degenhardt L, 2019, 'Regulatory and other responses to the pharmaceutical opioid problem', Medical Journal of Australia, 210, http://dx.doi.org/10.5694/mja2.12047

Nielsen S; Lintzeris N; Murnion B; Degenhardt L; Bruno R; Haber P; Johnson J; Hardy M; Ling S; Saddler C; Dunlop A; Demirkol A; Silsbury C; Phung N; Houseman J; Larance B, 2018, 'Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence', Drug and Alcohol Review, 37, pp. 887 - 896, http://dx.doi.org/10.1111/dar.12859

Pikovsky M; Peacock A; Larney S; Larance B; Conroy E; Nelson E; Degenhardt L, 2018, 'Alcohol use disorder and associated physical health complications and treatment amongst individuals with and without opioid dependence: A case-control study', Drug and Alcohol Dependence, 188, pp. 304 - 310, http://dx.doi.org/10.1016/j.drugalcdep.2018.04.016

Campbell G; Hall WD; Peacock A; Lintzeris N; Bruno R; Larance B; Nielsen S; Cohen M; Chan G; Mattick RP; Blyth F; Shanahan M; Dobbins T; Farrell M; Degenhardt L, 2018, 'Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study', The Lancet Public Health, 3, pp. e341 - e350, http://dx.doi.org/10.1016/S2468-2667(18)30110-5

Griffiths S; Jacka B; Degenhardt L; Murray SB; Larance B, 2018, 'Physical appearance concerns are uniquely associated with the severity of steroid dependence and depression in anabolic–androgenic steroid users', Drug and Alcohol Review, 37, pp. 664 - 670, http://dx.doi.org/10.1111/dar.12688

Blanch B; Degenhardt L; Buckley NA; Gisev N; Dobbins T; Karanges EA; Larance B; Larney S; Pearson SA, 2018, 'Prescription opioid access patterns and factors associated with increasing number of prescribers, pharmacies, and dispensings: An observational study using pharmaceutical claims', Pain Medicine (United States), 19, pp. 1170 - 1183, http://dx.doi.org/10.1093/pm/pnx035

Gisev N; Pearson SA; Karanges EA; Larance B; Buckley NA; Larney S; Dobbins T; Blanch B; Degenhardt L, 2018, 'To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?', Pharmacoepidemiology and Drug Safety, 27, pp. 550 - 555, http://dx.doi.org/10.1002/pds.4329

Larance B; Gisev N; Cama E; Nelson EC; Darke S; Larney S; Degenhardt L, 2018, 'Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence', Drug and Alcohol Dependence

Schaffer A; Buckley NA; Degenhardt L; Larance B; Cairns R; Dobbins T; Pearson SA, 2018, 'Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia', Canadian Medical Association Journal, 190, pp. E355 - E362, http://dx.doi.org/10.1503/cmaj.170666

Gisev N; Larance B; Cama E; Nielsen S; Roxburgh A; Bruno R; Degenhardt L, 2018, 'A nationwide study of the extent and factors associated with fentanyl use in Australia', Research in Social and Administrative Pharmacy, 14, pp. 303 - 308, http://dx.doi.org/10.1016/j.sapharm.2017.04.002

Nielsen S; Peacock A; Lintzeris N; Bruno R; Larance B; Degenhardt L, 2018, 'Knowledge of opioid overdose and attitudes to supply of take-home naloxone among people with chronic noncancer pain prescribed opioids', Pain Medicine (United States), 19, pp. 533 - 540, http://dx.doi.org/10.1093/pm/pnx021

Peacock A; Larance B; Farrell M; Cairns R; Buckley N; Degenhardt L, 2018, 'Opioid use and harms associated with a sustained-release tapentadol formulation: A postmarketing study protocol', BMJ Open, 8, http://dx.doi.org/10.1136/bmjopen-2017-020006

Cooper S; Campbell G; Larance B; Murnion B; Nielsen S, 2018, 'Perceived stigma and social support in treatment for pharmaceutical opioid dependence', Drug and Alcohol Review, 37, pp. 262 - 272, http://dx.doi.org/10.1111/dar.12601

Larance B; Dobbins T; Peacock A; Ali R; Bruno R; Lintzeris N; Farrell M; Degenhardt L, 2018, 'The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study', The Lancet Psychiatry, 5, pp. 155 - 166, http://dx.doi.org/10.1016/S2215-0366(18)30003-8

Holliday S; Hayes C; Dunlop A; Morgan S; Tapley A; Henderson K; Larance B; Magin P, 2017, 'Protecting pain patients. The evaluation of a chronic pain educational intervention', Pain Medicine (United States), 18, pp. 2306 - 2315, http://dx.doi.org/10.1093/pm/pnx018

Larance B; Degenhardt L; Peacock A; Gisev N; Mattick R; Colledge S; Campbell G, 2017, 'Pharmaceutical opioid use and harm in Australia: The need for proactive and preventative responses', Drug and Alcohol Review, http://dx.doi.org/10.1111/dar.12617

Jacka B; Peacock A; Degenhardt L; Bruno R; Clare P; Kemp R; Dev A; Larance B, 2017, 'Trends in PIEDs use among male clients of needle–syringe programs in Queensland, Australia; 2007–2015', International Journal of Drug Policy, 46, pp. 74 - 78, http://dx.doi.org/10.1016/j.drugpo.2017.05.048

Nielsen S; Gisev N; Bruno R; Hall W; Cohen M; Larance B; Campbell G; Shanahan M; Blyth F; Lintzeris N; Pearson S; Mattick R; Degenhardt L, 2017, 'Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment', Pharmacoepidemiology and Drug Safety, 26, pp. 587 - 591, http://dx.doi.org/10.1002/pds.4168

Nielsen S; Larance B; Lintzeris N, 2017, 'Opioid agonist treatment for patients with dependence on prescription opioids', JAMA - Journal of the American Medical Association, 317, pp. 967 - 968, http://dx.doi.org/10.1001/jama.2017.0001

Nielsen S; Larance B; Degenhardt L; Gowing L; Lintzeris N, 2017, 'A systematic review of opioid agonist treatments for pharmaceutical opioid dependence', DRUG AND ALCOHOL DEPENDENCE, 171, pp. E152 - E153, http://dx.doi.org/10.1016/j.drugalcdep.2016.08.421

Campbell G; Bruno R; Cohen M; Hall W; Nielsen S; Lintzeris N; Larance B; Mattick RP; Farrell M; Degenhardt L, 2017, 'Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic non-cancer pain: Different measures, same patients?', DRUG AND ALCOHOL DEPENDENCE, 171, pp. E33 - E33, http://dx.doi.org/10.1016/j.drugalcdep.2016.08.103

Peacock A; Bruno R; Larance B; Lintzeris N; Ali R; Oen D; Sotade O; White N; Degenhardt L, 2017, 'Same-day use of opioids and depressants: A retrospective diary study', DRUG AND ALCOHOL DEPENDENCE, 171, pp. E161 - E161, http://dx.doi.org/10.1016/j.drugalcdep.2016.08.444

Larney S; Cama E; Nelson E; Larance B; Degenhardt L, 2016, 'A cross-sectional study of correlates of imprisonment in opioid-dependent men and women in New South Wales, Australia', Drug and Alcohol Review, 35, pp. 686 - 692, http://dx.doi.org/10.1111/dar.12357

Peacock A; Nielsen S; Bruno R; Campbell G; Larance B; Degenhardt L; Peacock A, 2016, 'Geographic variation in health service use and perceived access barriers for Australian adults with chronic non-cancer pain receiving opioid therapy', Pain Medicine (United States), 17, pp. 2003 - 2016, http://dx.doi.org/10.1093/pm/pnw109

Deacon RM; Nielsen S; Leung S; Rivas G; Cubitt T; Monds LA; Ezard N; Larance B; Lintzeris N, 2016, 'Alprazolam use and related harm among opioid substitution treatment clients – 12 months follow up after regulatory rescheduling', International Journal of Drug Policy, 36, pp. 104 - 111, http://dx.doi.org/10.1016/j.drugpo.2016.06.006

Larance B; Copeland J; Burns L; Holden J; Farrell M; Degenhardt L, 2016, 'PHYSICAL HEALTH AND OPPORTUNITIES FOR INTERVENTION AMONG MEN WHO USE PERFORMANCE AND IMAGE ENHANCING DRUGS', DRUG AND ALCOHOL REVIEW, 35, pp. 47 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398381500129&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Peacock A; Bruno R; Larance B; Lintzeris N; Nielsen S; Ali R; Dobbins T; Degenhardt L; Peacock A, 2016, 'Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study', Drug and Alcohol Dependence, 166, pp. 125 - 133, http://dx.doi.org/10.1016/j.drugalcdep.2016.07.003

Campbell G; Bruno R; Lintzeris N; Cohen M; Nielsen S; Hall W; Larance B; Mattick RP; Blyth F; Farrell M; Degenhardt L, 2016, 'Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: Do different measures identify the same patients?', Pain, 157, pp. 1489 - 1498, http://dx.doi.org/10.1097/j.pain.0000000000000548

Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N, 2016, 'Opioid agonist treatment for pharmaceutical opioid dependent people', Cochrane Database of Systematic Reviews, 2016, pp. cd011117, http://dx.doi.org/10.1002/14651858.CD011117.pub2

Larance B; Campbell G; Peacock A; Nielsen S; Bruno R; Hall W; Lintzeris N; Cohen M; Degenhardt L; Peacock A, 2016, 'Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy', Drug and Alcohol Dependence, 162, pp. 79 - 87, http://dx.doi.org/10.1016/j.drugalcdep.2016.02.048

Degenhardt L; Gisev N; Cama E; Nielsen S; Larance B; Bruno R, 2016, 'The extent and correlates of community-based pharmaceutical opioid utilisation in Australia', Pharmacoepidemiology and Drug Safety, 25, pp. 521 - 538, http://dx.doi.org/10.1002/pds.3931

Gisev N; Nielsen S; Cama E; Larance B; Bruno R; Degenhardt L, 2016, 'An ecological study of the extent and factors associated with the use of prescription and over-the-counter codeine in Australia', European Journal of Clinical Pharmacology, 72, pp. 469 - 494, http://dx.doi.org/10.1007/s00228-015-1995-8

Larance B; Bruno R; Lintzeris N; Degenhardt L; Black E; Brown A; Nielsen S; Dunlop A; Holland R; Cohen M; Mattick RP, 2016, 'Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours In Treatment (ORBIT) scale', Drug and Alcohol Dependence, 159, pp. 42 - 52, http://dx.doi.org/10.1016/j.drugalcdep.2015.11.026

Larance B; Mattick R; Ali R; Lintzeris N; Jenkinson R; White N; Kihas I; Cassidy R; Degenhardt L, 2016, 'Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia', Drug and Alcohol Review, 35, pp. 83 - 91, http://dx.doi.org/10.1111/dar.12344

Gisev N; Pearson SA; Blanch B; Larance B; Dobbins T; Larney S; Degenhardt L, 2016, 'Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated', British Journal of Clinical Pharmacology, pp. 1123 - 1133, http://dx.doi.org/10.1111/bcp.13026

Lintzeris N; Moodley R; Campbell G; Larance B; Bruno R; Nielsen S; Degenhardt L, 2016, 'Sleep quality among people living with chronic noncancer pain: Findings from the pain and opioids in treatment (POINT) cohort', Clinical Journal of Pain, 32, pp. 380 - 387, http://dx.doi.org/10.1097/AJP.0000000000000282

White N; Ali R; Larance B; Zador D; Mattick RP; Degenhardt L, 2016, 'The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film', Drug and Alcohol Review, 35, pp. 76 - 82, http://dx.doi.org/10.1111/dar.12317

Peacock AK; Degenhardt L; Campbell G; Larance B; Nielsen S; Hall W; Mattick RP; Bruno R; Peacock A, 2016, 'A typology of predictive risk factors for non-adherent medication-related behaviors among chronic non-cancer pain patients prescribed opioids: a cohort study', Pain Physician, 19, pp. e421 - e434, http://dx.doi.org/10.36076/ppj/2019.19.e421

Peacock A; Degenhardt L; Larance B; Cama E; Lintzeris N; Ali R; Bruno R, 2015, 'A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone', Pharmacoepidemiology and Drug Safety, 24, pp. 1321 - 1333, http://dx.doi.org/10.1002/pds.3883

White N; Flaherty I; Higgs P; Larance B; Nielsen S; Degenhardt L; Ali R; Lintzeris N, 2015, 'Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study', Drug and Alcohol Review, 34, pp. 623 - 629, http://dx.doi.org/10.1111/dar.12308

Peacock A; Bruno R; Cama E; Kihas I; Larance B; Lintzeris N; Hordern A; White N; Ali R; Degenhardt L, 2015, 'Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids', Drug and Alcohol Review, 34, pp. 611 - 622, http://dx.doi.org/10.1111/dar.12279

Nielsen S; Larance B; Lintzeris N; Holliday S; Vanderhaven M; Hordern A; Dunlop A; Haber PS; Murnion B; Silsbury C; Johnson J; Demirkol A; Sadler C; Phung N; Campbell G; Farrell M; Cohen M; Bruno R; Hardy M; Brown A; Houseman J; Degenhardt L, 2015, 'LONGER TERM OUTCOMES FOR PHARMACEUTICAL OPIOID DEPENDENCE: 12 MONTH FINDINGS FROM AN IN-TREATMENT COHORT', DRUG AND ALCOHOL REVIEW, 34, pp. 48 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000367694000129&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Larance B; Lintzeris N; Bruno R; Peacock A; Cama E; Ali R; Kihas I; Hordern A; White N; Degenhardt L, 2015, 'The characteristics of a cohort who tamper with prescribed and diverted opioid medications', Journal of Substance Abuse Treatment, 58, pp. 51 - 61, http://dx.doi.org/10.1016/j.jsat.2015.06.001

Larance B; Dietze P; Ali R; Lintzeris N; White N; Jenkinson R; Degenhardt L, 2015, 'The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations', Drug and Alcohol Review, 34, pp. 603 - 610, http://dx.doi.org/10.1111/dar.12277

Hoban B; Larance B; Gisev N; Nielsen S; Cohen M; Bruno R; Shand F; Lintzeris N; Hall W; Farrell M; Degenhardt L, 2015, 'The use of paracetamol (acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids', International Journal of Clinical Practice, 69, pp. 1366 - 1376, http://dx.doi.org/10.1111/ijcp.12716

Degenhardt L; Gisev N; Cama E; Larance B; Bruno R, 2015, 'Estimating the Extent and Predictors of Pharmaceutical Opioid Use in Australia in 2013', PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 24, pp. 25 - 26, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000369980200044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Campbell G; Nielsen S; Larance B; Bruno R; Mattick R; Hall W; Lintzeris N; Cohen M; Smith K; Degenhardt L, 2015, 'Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort', Pain Medicine (United States), 16, pp. 1745 - 1758, http://dx.doi.org/10.1111/pme.12773

Smith K; Mattick RP; Bruno R; Nielsen S; Cohen M; Campbell G; Larance B; Farrell M; Degenhardt L, 2015, 'Factors associated with the development of depression in chronic non-cancer pain patients following the onset of opioid treatment for pain', Journal of Affective Disorders, 184, pp. 72 - 80, http://dx.doi.org/10.1016/j.jad.2015.05.049

Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B, 2015, 'The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study', Drug and Alcohol Dependence, 151, pp. 56 - 67, http://dx.doi.org/10.1016/j.drugalcdep.2015.02.038

Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L, 2015, 'A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia', Addiction, 110, pp. 646 - 655, http://dx.doi.org/10.1111/add.12834

Back to profile page